Future market – Worth about USD 50 billion: Illumina, Moderna, PanGenomic Health

Moderna: Individual mRNA therapy against cancer

When market researchers take a closer look at personalized medicine, they typically distinguish between therapeutics, i.e. specific active ingredients, diagnostics, and digital health solutions. In the field of therapeutics, the US company Moderna caused a stir during the pandemic with an mRNA vaccine. Even though its Mainz-based competitor BioNTech was slightly faster off the mark, the US company also managed to enter the billion-dollar market for COVID-19 vaccines in time. Moderna is still benefiting twice over from this pioneering achievement. Firstly, its COVID-19 vaccines are still generating revenue, and secondly, the knowledge surrounding mRNA can be used in personalized cancer medicine. In Intismeran therapy, in which Moderna is collaborating with Merck, the mRNA vaccine molecule encodes the specific neoantigens of a patient's tumor to trigger a targeted immune response. Initial data from this approach are promising and offer hope for other indications, such as renal cell carcinoma, bladder cancer, and cutaneous squamous cell carcinoma. A key advantage of mRNA technology is its rapid cycle manufacturing, which enables small batches and thus patient-specific vaccines.

Illumina unlocks the secret of life

Illumina is more active in the field of diagnostics. As the undisputed market leader in genome sequencing, Illumina is the go-to company for hospitals and laboratories worldwide and has played a key role in reducing the cost of sequencing a human genome from over USD 100 million at the beginning of the millennium to just USD 200 today. Illumina's business model is characterized by a combination of hardware sales and recurring revenues. Illumina generates most of its revenue not from the sequencing machines themselves but from related consumables such as swabs and carrier mats. This makes the business predictable.

PanGenomic Health: AI app as a health coach

The young company PanGenomic Health is pursuing a particularly innovative and, above all, low-cost business model. The Canadians are active in the field of digital health solutions and use their Nara.AI platform to leverage the latest technology to help people achieve personal well-being, stay healthy for longer, and treat specific ailments themselves. It is like having a health coach in your pocket. The app draws on the latest research findings and also enables constant feedback from patients so that treatment and dosage can be adjusted if necessary. At the heart of PanGenomic Health is its online shop for supplements and other active ingredients. In this context, it is important to note that PanGenomic focuses on the US and Canada. There, dietary supplements are much more liberally regulated, and even medical precursors and intermediates such as peptides are available for sale. These are extremely potent and can, for example, interfere with the hormonal balance.

Growth drivers: High treatment costs and the longevity hype

PanGenomic Health's offering strikes a chord with many customers: First, the fitness hype and longevity trend are driving more and more users to actively manage and maintain their health even without major complaints. The threshold for taking supplements or other active ingredients is also falling significantly – doing something good for oneself is trending. In the US, this is compounded by the fact that healthcare costs are very high and fewer and fewer Americans can afford traditional treatment. Guided by smart AI and supplied with potent substances from its web shop, users may be able to manage certain conditions themselves. The market for PanGenomic's solutions is, therefore, well established. The Company has declared **2025 the "Year of Growth" and is currently doing everything possible to roll out its services across North America.

While companies such as Moderna and Illumina have had to conduct years of research to bring their technology to market, PanGenomic Health benefits both from the findings of this research and from the liberal market for dietary supplements and digital health offerings. Instead of investing millions in expensive research, the AI-based platform Nara.AI can offer individualized therapy options, monitor them continuously in collaboration with patients, and monetize them through an affiliated webshop. Experts such as the analysts at McKinsey also highlight this trend in their market study "AI-driven enterprise: Charting a path to 2030", noting that business models based on AI and data ecosystems have excellent prospects for the future.

Top story, great prospects, and low valuation: PanGenomic Health

With a market capitalization of EUR 3.2 million, PanGenomic Health is still a micro-cap, although the stock has recently been gaining momentum. To benefit from the trend toward personalized medicine, the stock offers greater leverage than Illumina or Moderna, for example. These stocks have fallen by nearly 27% and 44% in the last six months. Although both stocks are repeatedly showing signs of recovery, a trend reversal is still a long way off. Speculative investors looking to benefit from the trend toward personalized medicine may want to take a closer look at PanGenomic Health. Given the low liquidity on German stock exchanges, investors should set tight limits on orders or consider trading directly in Canada.